- Home
- ENSC vs PRPH Comparison
ENSC vs PRPH Comparison
Compare ENSC & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- PRPH
- Stock Information
- Founded
- ENSC 2003
- PRPH 1989
- Country
- ENSC United States
- PRPH United States
- Employees
- ENSC N/A
- PRPH N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- PRPH Health Care
- Exchange
- ENSC Nasdaq
- PRPH Nasdaq
- Market Cap
- ENSC 7.9M
- PRPH 7.8M
- IPO Year
- ENSC N/A
- PRPH 1997
- Fundamental
- Price
- ENSC $5.40
- PRPH $0.53
- Analyst Decision
- ENSC
- PRPH Strong Buy
- Analyst Count
- ENSC 0
- PRPH 1
- Target Price
- ENSC N/A
- PRPH $11.00
- AVG Volume (30 Days)
- ENSC 26.4K
- PRPH 26.5M
- Earning Date
- ENSC 03-14-2025
- PRPH 03-14-2025
- Dividend Yield
- ENSC N/A
- PRPH N/A
- EPS Growth
- ENSC N/A
- PRPH N/A
- EPS
- ENSC N/A
- PRPH N/A
- Revenue
- ENSC $4,421,404.00
- PRPH $12,753,000.00
- Revenue This Year
- ENSC $89.78
- PRPH $36.93
- Revenue Next Year
- ENSC N/A
- PRPH $132.05
- P/E Ratio
- ENSC N/A
- PRPH N/A
- Revenue Growth
- ENSC 40.41
- PRPH N/A
- 52 Week Low
- ENSC $2.12
- PRPH $0.22
- 52 Week High
- ENSC $14.67
- PRPH $7.48
- Technical
- Relative Strength Index (RSI)
- ENSC 35.78
- PRPH 57.09
- Support Level
- ENSC $5.34
- PRPH $0.28
- Resistance Level
- ENSC $6.14
- PRPH $0.78
- Average True Range (ATR)
- ENSC 0.43
- PRPH 0.10
- MACD
- ENSC -0.04
- PRPH 0.05
- Stochastic Oscillator
- ENSC 9.49
- PRPH 56.07
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.